Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
81,000
Employees81,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
81,000
Employees81,000

PFE Key Statistics

Market cap
151.67B
Market cap151.67B
Price-Earnings ratio
19.75
Price-Earnings ratio19.75
Dividend yield
6.40%
Dividend yield6.40%
Average volume
45.11M
Average volume45.11M
High today
$26.89
High today$26.89
Low today
$26.36
Low today$26.36
Open price
$26.71
Open price$26.71
Volume
44.78M
Volume44.78M
52 Week high
$27.94
52 Week high$27.94
52 Week low
$20.92
52 Week low$20.92

Stock Snapshot

With a market cap of 151.67B, Pfizer(PFE) trades at $26.65. The stock has a price-to-earnings ratio of 19.75 and currently yields dividends of 6.4%.

During the trading session on 2026-02-20, Pfizer(PFE) shares reached a daily high of $26.89 and a low of $26.36. At a current price of $26.65, the stock is +1.1% higher than the low and still -0.9% under the high.

Trading volume for Pfizer(PFE) stock has reached 44.78M, versus its average volume of 45.11M.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.94 and a low of $20.92.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.94 and a low of $20.92.

PFE News

Nasdaq 1h
Is Pfizer Stock an Underrated Healthcare Investment Play?

Key Points The stock offers a lofty 6.2% yield, and management has declared its intent to support its dividend. The pharmaceutical giant has fallen behind com...

Is Pfizer Stock an Underrated Healthcare Investment Play?
Nasdaq 15h
Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash?

Key Points Pfizer has reached a transition point following declines of some of its biggest blockbusters. The pharma giant is paving the way to growth through...

Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash?
TipRanks 1d
Pfizer initiated with an Underweight at Barclays

Barclays analyst Emily Field initiated coverage of Pfizer (PFE) with an Underweight rating and $25 price target Pfizer is “managing through a difficult period,”...

Analyst ratings

59%

of 29 ratings
Buy
34.5%
Hold
58.6%
Sell
6.9%

More PFE News

Simply Wall St 1d
Pfizer's BRAFTOVI Trial Win Adds Weight To Undervalued Oncology Story

Pfizer (NYSE:PFE) reported positive pivotal Phase 3 trial results for BRAFTOVI in combination with cetuximab and FOLFIRI in BRAF V600E-mutant metastatic colorec...

Pfizer's BRAFTOVI Trial Win Adds Weight To Undervalued Oncology Story
Bloomberg 1d
Pfizer Ponders Viagra Lessons to Chart First Obesity Drug Launch

Pfizer Inc. is drawing on lessons learned years ago from rolling out Viagra as it maps out the launch of its first obesity medicine. The parallels between weig...

Pfizer Ponders Viagra Lessons to Chart First Obesity Drug Launch
TipRanks 2d
Mixed options sentiment in Pfizer with shares down 0.2%

Mixed options sentiment in Pfizer (PFE), with shares down 6c near $27.32. Options volume relatively light with 33k contracts traded and calls leading puts for a...

TipRanks 2d
Pfizer Targets Real-World Myeloma Data in Taiwan With New Elranatamab Study

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) is launching a new real-world study in Taiwan to track how its multiple...

Simply Wall St 3d
Pfizer’s BRAFTOVI Data Adds New Dimension To Oncology Growth Story

Pfizer reported positive pivotal results from its BREAKWATER trial for the BRAFTOVI based regimen in first line treatment of BRAF V600E mutant metastatic colore...

Pfizer’s BRAFTOVI Data Adds New Dimension To Oncology Growth Story
Benzinga 3d
Pfizer's Cancer Drug Combo Shows Strong Results In Key Colorecatal Cancer Trial

Pfizer Inc. (NYSE:PFE) on Tuesday shared news regarding its BRAFTOVI regimen for treating metastatic colorectal cancer. Pfizer announced that its Braftovi regi...

Pfizer's Cancer Drug Combo Shows Strong Results In Key Colorecatal Cancer Trial
Seeking Alpha 3d
Pfizer says cancer therapy Braftovi improved survival in late-stage trial

Pfizer (PFE) announced on Tuesday that its colorectal cancer therapy, Braftovi, as part of a combination regimen, improved patient survival, reaching a key seco...

Pfizer says cancer therapy Braftovi improved survival in late-stage trial

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.